Urine cytology is one test used in the diagnosis of bladder cancer,
but it has low sensitivity. Grossman and colleagues investigated whether a
proteomic assay for a tumor marker, nuclear matrix protein NMP22, in voided
urine and available at point-of-care, could improve detection of malignancy
in patients with risk factors or symptoms of bladder cancer. The authors found
that the NMP22 assay to have positive results in 44 of 79 patients with confirmed
bladder cancer, including 4 tumors not seen on cystoscopy, whereas urine cytology
had positive results in only 12 of 76 patients.